News

GS-9131, a novel nucleoside reverse transcriptase inhibitor, is a promising antiretroviral candidate for individuals displaying resistance to other NRTIs.

A fast switch to second-line ART after observation of elevated VL or CD4

The opioid overdose death rate for persons living with HIV was 42.7% greater in 2015 than in 2011 even though the total death rate among HIV-diagnosed individuals decreased.

The FLAIR trial evaluated whether a switch to monthly long-acting injectable cabotegravir /rilpivirine is non-inferior to oral dolutegravir/ abacavir /lamivudine in treatment-naive adults.

The ATLAS trial evaluated whether a switch to monthly long-acting injectable cabotegravir/rilpivirine is non-inferior to continued 3-drug oral antiretroviral therapy in virologically suppressed adults.

Saye Khoo, MD, lead presenter of DOLPHIN-2, explains the details of the research on the differences between efavirenz regimen and dolutegravir when initatied during the third trimester of pregnancy.

The HPV vaccine appears to be doing what it was intended to do—lowering rates of cervical cancer, particularly HPV types 16 and 18, responsible for most cases worldwide.

A study reports that weight gain in individuals on ART was associated with lower BMI, reduced proportion of hypogonadism, increased proportion of psychiatric disorders, and non-PI-containing regimens.

A study characterizes the genotypic profile and the phenotypic susceptibility to temsavir in patients with multidrug resistant HIV who could be candidates for fostemsavir.

Investigators report 12-month outcomes from the Botswana Epidemiological ART Treatment Cohort Study (BEAT), an observational research cohort tracking virologic and clinical outcomes of people living with HIV who are beginning dolutegravir-based regimens.

Using EHR data, a study team identified 6076 potential PrEP candidates in a large health system, of whom 5577 (92%) were not on PrEP at the time.

PrEP use in persons with undetected HIV infections contributes to drug resistance and has investigators urging regular screening.

HIV incidence rates in MSM and transgender women taking F/TAF or F/TDF were found to be very low and significantly less than the rate in at-risk individuals not on PrEP in the US.

With 206 cases of measles reported so far in 11 states in 2019, a new study noting that there is no connection between the measles, mumps, rubella (MMR) vaccine and autism has been released.

The rise of Shingrix as a first-choice prophylaxis for shingles has lead to increased demand as the manufacturer commits to ramping up production.

Following FDA approval of a single-tablet bictegravir, emtricitabine, and tenofovir alafenamide regimen for use in adults with HIV, investigators are exploring the safety and efficacy of the same therapy in children and adolescents aged 6 to 18 years.

Weight gain is often a concern for patients on ART. But what about the metabolic impact of PrEP on HIV-uninfected individuals?

DOLPHIN-2 reports that dolutegravir is well-tolerated and achieves more rapid virological suppression prior to delivery compared to efavirenz when initiated during pregnancy.

Bacterial sexually transmitted infections are still prevalent among men who have sex with men in England, but PrEP and other measures have sharply cut the rate of new HIV diagnoses.

A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.

Prior studies have indicated that patients with influenza A infections fare worse than those with influenza B, and now a new study backs it up.

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has been fighting HIV/AIDS since the 1980s when the virus was first discovered. Now, thanks to a joint effort by multiple arms of the US Department of Health and Human Services, he’s making headway.

Investigators from England report the longest adult HIV remission observed since the Berlin patient.

Over a 12-month study, there was a 13.9% increase of retention with viral load suppression among participants who received rapid viral load results following point-of-care testing.

Vaccine-preventable disease outbreaks are on the rise and social media has a responsibility to help rein it in

Investigators in Denmark showed that a cocktail of common antibiotics could fight resistant E coli and treat urinary tract infections after determining that resistance toward 1 drug leads to sensitivity to another.

Recognizing that many college students are in the riskiest category, agewise, for HIV, new guidelines aim to help providers be more proactive about PrEP.

Influenza vaccines may be less effective in older adults due to a lack of antibody diversity, a new study suggests.

We’ve rounded up a list of important US Food and Drug Administration and US Department of Agriculture recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.